E-LIB Suche - Ergebnisse für: Shunsuke Teraoka, MD

1

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSC..:

Hidetoshi Hayashi, MD, PhD ; Shunsuke Teraoka, MD ; Yasushi Goto, MD, PhD...
http://www.sciencedirect.com/science/article/pii/S2666364323000103. , 2023

Link: https://doi.org/10.1016/..

2

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Stu..:

Qing Zhou, MD, PhD ; Ross A. Soo, MBBS, PhD ; Gee-Chen Chang, MD, PhD...
http://www.sciencedirect.com/science/article/pii/S2666364323000383. , 2023

Link: https://doi.org/10.1016/..

3

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC ..:

Kiichiro Ninomiya, MD, PhD ; Shunsuke Teraoka, MD ; Yoshitaka Zenke, MD, PhD...
http://www.sciencedirect.com/science/article/pii/S2666364320301533. , 2021

Link: https://doi.org/10.1016/..

4

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC..:

Hiroaki Akamatsu, MD, PhD ; Shunsuke Teraoka, MD ; Hidetoshi Hayashi, MD, PhD...
http://www.sciencedirect.com/science/article/pii/S2666364321000436. , 2021

Link: https://doi.org/10.1016/..

5

A Phase II Study of High-Flow Nasal Cannula for Relieving D..:

Takase, Eri ; Akamatsu, Hiroaki ; Teraoka, Shunsuke...
Journal of Pain and Symptom Management. 67 (2024) 3 - p. 204-211.e1 , 2024

Link: https://doi.org/10.1016/..

6

Association of immune-related adverse events with durvaluma..:

Haratani, Koji ; Nakamura, Atsushi ; Mamesaya, Nobuaki...
British Journal of Cancer. 130 (2024) 11 - p. 1783-1794 , 2024

Link: https://doi.org/10.1038/..

7

Mannitol versus furosemide in patients with thoracic malign..:

Murakami, Eriko ; Akamatsu, Hiroaki ; Teraoka, Shunsuke...
Cancer Medicine. 13 (2024) 4 - p. , 2024

Link: https://doi.org/10.1002/..

8

Long-Term Efficacy and Safety of Lorlatinib in Japanese Pat..:

Teraoka, Shunsuke ; Hayashi, Hidetoshi ; Goto, Yasushi...
JTO Clinical and Research Reports. 5 (2024) 3 - p. 100632 , 2024

Link: https://doi.org/10.1016/..

9

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSC..:

Hayashi, Hidetoshi ; Teraoka, Shunsuke ; Goto, Yasushi...
JTO Clinical and Research Reports. 4 (2023) 4 - p. 100471 , 2023

Link: https://doi.org/10.1016/..

10

Afatinib plus osimertinib in the treatment of osimertinib-r..:

Miura, Satoru ; Koh, Yasuhiro ; Azuma, Koichi...
BMC Cancer. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

11

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlat..:

Soo, Ross A. ; Martini, Jean-François ; van der Wekken, Anthonie J....
Journal of Thoracic Oncology. 18 (2023) 11 - p. 1568-1580 , 2023

Link: https://doi.org/10.1016/..

12

Tumor Microenvironment Landscape of NSCLC Reveals Resistanc..:

Haratani, Koji ; Nakamura, Atsushi ; Mamesaya, Nobuaki...
Journal of Thoracic Oncology. 18 (2023) 10 - p. 1334-1350 , 2023

Link: https://doi.org/10.1016/..

13

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Stu..:

Zhou, Qing ; Soo, Ross A. ; Chang, Gee-Chen...
JTO Clinical and Research Reports. 4 (2023) 5 - p. 100499 , 2023

Link: https://doi.org/10.1016/..

14

Liquid biopsy detects genomic drivers in NSCLC without EGFR..:

Uemura, Takehiro ; Kenmotsu, Hirotsugu ; Hazama, Daisuke...
Cancer Medicine. 12 (2023) 23 - p. 21097-21110 , 2023

Link: https://doi.org/10.1002/..

15

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Ve..:

Kenmotsu, Hirotsugu ; Wakuda, Kazushige ; Mori, Keita...
Journal of Thoracic Oncology. 17 (2022) 9 - p. 1098-1108 , 2022

Link: https://doi.org/10.1016/..